SHENZHEN, China & ROCKVILLE, Md.
HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that Company’s Management will provide a corporate presentation and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference to be held May 10-13, 2021.
HighTide will present at 8:00am EDT on Thursday, May 13, 2021.
About HighTide Therapeutics
HighTide Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutics for non-viral chronic liver diseases, gastrointestinal diseases and metabolic disorders, with a focus on areas of high unmet medical need and lack of effective treatment options.
About HTD1801
HighTide’s lead product candidate, HTD1801, an ionic salt of berberine and ursodeoxycholic acid, is a first-in-class drug and new molecular entity being developed for the treatment of primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and primary biliary cholangitis (PBC). HTD1801 has received Fast Track designation from the U.S. FDA for both PSC and NASH, as well as Orphan Drug designation for PSC. For additional information, please visit https://hightidetx.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005045/en/
CONTACT
Investor relations:
Jeffrey Dao
ir@hightidetx.com
Media relations:
Grace Zhang
media@hightidetx.com
